Share on StockTwits
 

Shares of Valeant Pharmaceuticals (NYSE:VRX) hit a new 52-week high during trading on Wednesday, Analyst RN reports. The stock traded as high as $136.20 and last traded at $133.41, with a volume of 961,156 shares trading hands. The stock had previously closed at $135.01.

A number of research firms have recently commented on VRX. Analysts at UBS AG raised their price target on shares of Valeant Pharmaceuticals from $125.00 to $141.00 in a research note to investors on Wednesday, January 8th. They now have a “buy” rating on the stock. Separately, analysts at TD Securities downgraded shares of Valeant Pharmaceuticals from a “buy” rating to a “hold” rating in a research note to investors on Wednesday, January 8th. Finally, analysts at Ladenburg Thalmann raised their price target on shares of Valeant Pharmaceuticals from $123.00 to $155.00 in a research note to investors on Wednesday, January 8th. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $127.96.

In other Valeant Pharmaceuticals news, Director Norma Ann Provencio sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $133.00, for a total value of $665,000.00. Following the transaction, the director now directly owns 152,206 shares in the company, valued at approximately $20,243,398. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Valeant Pharmaceuticals has a 52-week low of $63.05 and a 52-week high of $135.73. The stock has a 50-day moving average of $114.5 and a 200-day moving average of $104.9. The company’s market cap is $44.574 billion.

Valeant Pharmaceuticals (NYSE:VRX) last announced its earnings results on Thursday, October 31st. The company reported $1.51 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.40 by $0.11. The company had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $884.14 million. During the same quarter last year, the company posted $1.15 earnings per share. Valeant Pharmaceuticals’s revenue was up 74.4% compared to the same quarter last year. On average, analysts predict that Valeant Pharmaceuticals will post $6.14 earnings per share for the current fiscal year.

Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.